Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nesvategrast - OcuTerra Therapeutics

Next Previous
Drug Profile

Nesvategrast - OcuTerra Therapeutics

Alternative Names: OTT-166; SF-0166

Latest Information Update: 19 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SciFluor Life Sciences
  • Developer OcuTerra Therapeutics
  • Class Eye disorder therapies; Imidazolidines; Naphthyridines; Propionic acids; Pyridines; Small molecules
  • Mechanism of Action Integrin alphaVbeta3 antagonists; Integrin alphaVbeta6 inhibitors; Integrin alphavbeta8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic retinopathy
  • Phase I/II Diabetic macular oedema
  • No development reported Wet age-related macular degeneration

Most Recent Events

  • 14 Mar 2024 Efficacy and adverse event data from the phase II DR:EAM trial in Diabetic retinopathy released by OcuTerra Therapeutics
  • 29 Dec 2023 OcuTerra Therapeutics completes a phase II DR:EAM trial in Diabetic retinopathy (Treatment-naive) in the US and Puerto Rico (NCT05409235)
  • 18 Jul 2023 OcuTerra Therapeutics completes enrolment in its phase II DR:EAM trial for Diabetic retinopathy (Treatment-naive) in USA (Ophthalmic) (NCT05409235)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top